Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are important for new drug development. We all want a treatment for lung cancer that is completely safe and entirely effective. While researchers are working toward that goal, the reality is we aren’t there yet. Every treatment we are considering comes with potential benefits and side effects. The overarching role of clinical trials is to measure the pros and cons of each drug to help us identify the best treatments for

Read time: 3 minutes. This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming weeks. Have you ever wondered how a new medicine or drug to treat lung cancer is brought to the people who need it? That’s what clinical trials help us do. According to the National Cancer Institute, a clinical trial is a type of research study that tests how well new medical approaches (such as screening tests, prevention habits, or disease treatments) work in people. Sometimes, a clinical trial is called a clinical

Read time: 3 minutes. One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment. You can register today for free, or view the conference agenda. Last year’s conference was one of our most successful events yet, with over 900

Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials. In the first of a three-part series, Rising Tide Foundation for Clinical Cancer Research has partnered with LUNGevity to understand the role people with lung cancer can play in developing clinical trials. Through panelist presentations and discussions, this video focuses on patient-centric endpoints, showcases this collaboration from the

On May 16, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of tarlatamab-dlle (Imdelltra®) to treat patients with extensive-stage small cell lung cancer (SCLC). This targeted immunotherapy, the first of its kind, is based on new technology. Tarlatamab is a bispecific T-cell engager (BiTE)—a drug with two arms that simultaneously binds to a T cell (a part of the immune system) and a tumor cell. This allows the T cell to come close enough to the tumor cell to recognize and destroy it. Tarlatamab is a second-line treatment that can be considered if chemotherapy

Read time: 2 minutes Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods. LUNGevity spoke to an expert to help sort out the facts from the fiction. In the webinar below, Gabriel Lopez, MD, medical director of the Integrative Medicine Center at MD Anderson Cancer Center, explains how integrative medicine can be safely

This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr. Moore addressed the critical issues posed by the chemotherapy shortage, offering valuable insights into its origins, impact on people with lung cancer, available alternatives, and ongoing efforts to address disparities. Her expertise provides essential understanding for anyone interested in the complexities of lung cancer

Lung cancer experts from Johns Hopkins Kimmel Cancer Center dive into the how and why behind targeted therapy, immunotherapy, and radiation therapy. Touching on improvements to treatment options, side effects, fertility, and much more, they answer audience questions along the way in this recorded webinar. Watch the full video or use the timestamps below to jump to a specific topic.

The four phases of lung cancer clinical trials each serve a different and important purpose. From testing the safety of a new treatment to its effectiveness and long-term outcomes, this short video explains how researchers use clinical trials for new lung cancer treatments. Phases of a Clinical Trial: 1. Safety of the new treatment 2. Does the cancer respond to the treatment 3. Is this new treatment better than the current options 4. Studies the long-term benefits and side effects

On November 15, 2023, the US Food and Drug Administration (FDA) announced the approval of repotrectinib to treat patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Repotrectinib is part of a class of drugs called tyrosine kinase inhibitors, or TKIs, which have been beneficial for many patients with oncogene-driven lung cancers. TKIs are a type of therapy that specifically targets changes in genes that are known to promote tumor growth. Repotrectinib is the third TKI drug for ROS1-positive NSCLC but is the first to be used for patients who either have